Introduction Allostatic load refers to the cumulative burden of stress and life events that involve the interaction of various physiological systems at differing levels of activity. Allostatic overload occurs when environmental challenges surpass an individual’s ability to cope. The COVID-19 pandemic has subjected pregnant women to an unprecedented amount of stress and uncertainty, and this situation has been linked to higher rates of mental health disorders, especially during lockdowns and the early stages of the pandemic. Contributing factors potentially include gender-based violence, gender inequality, multidimensional poverty, barriers to healthcare, isolation, and social restrictions, among others. Perinatal mental health disorders, such as anxiety, depression, and stress, have lasting health effects on both mothers and their children and could be significant risk factors for allostatic overload. Maternal mood and anxiety disorders during pregnancy have been linked to cardiovascular diseases, particularly ischemic heart disease, years after childbirth. Additionally, there is evidence showing the cardiovascular impacts of COVID-19, including an increased expression of thrombosis biomarkers in patients infected with SARS-CoV-2.

Aim To evaluate the impact of allostatic overload during pregnancy, particularly in the context of the COVID-19 pandemic, on mothers’ cardiovascular health, children’s neurodevelopment, and the mother-child relationship.

Study design We propose a historical cohort study focused on mothers who were pregnant during the COVID-19 pandemic (2020–2021). We will retrospectively assess exposure to allostatic overload during the perinatal period by triangulating both quantitative and qualitative data. The outcomes for mother-child dyads will be evaluated prospectively.

Methods We propose to study 32 exposed and 64 control subjects to reject the null hypothesis that the relative risk equals 1. This sample size was estimated to detect a significantly higher relative risk of ischemic heart disease. The primary outcomes will be: 1) Manifestation or higher risk of ischemic heart disease in the mothers. 2) Neurodevelopmental disorders in children. 3) Alterations in the mother and child relationship. To assess exposure to allostatic overload, we will conduct a clinimetric survey and narrative interviews to explore life experiences and identify significant stressors during the perinatal period. The potential association between allostatic overload and health later in life will be analysed using multivariable epidemiological analyses and machine learning techniques.

Expected results We anticipate a higher prevalence of allostatic overload in women who experienced pregnancy during the first wave of the COVID-19 pandemic compared to the later period. It is proposed that these women may face an increased risk of hypertension, endothelial dysfunction, and ischemic heart disease due to allostatic overload. Additionally, we expect to observe changes in plasma biomarkers related to cardiovascular health and a higher risk of neurodevelopmental disorders in their children. Furthermore, increased parental stress associated with allostatic overload during pregnancy may lead to a poorer mother-child relationship.

The authors have declared no competing interest.

Yes

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Ethics and Scientific Committee of the Concepción Health Service (CEC-SSC 24-03-10), Ethics Committee of Faculty of Medicine of the Universidad de Concepción (CEC 6/2024), and Ethics, Bioethics and Biosafety Committee of the Vicerrectoría de Investigación y Desarrollo (VRID) of Universidad de Concepción (CEBB 1689-2024).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

No datasets were generated or analysed during the current study. All relevant data from this study will be made available upon study completion.